Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP-R in Refractory CLL, AIHA, or Richter's Transformation
NCT00309881Phase 2Completed
- Sponsor
- German CLL Study Group
- Start
- Apr 2003
- Primary completion
- Mar 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic lymphocytic leukemia (CLL) and Richter's transformation (RT), sponsored by German CLL Study Group. Primary endpoints: Rate of remission, Quality of remission and 1 more. Started Apr 2003; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)Richter's transformation (RT)
Beyond the preview
Go deeper on NCT00309881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309881.